Luciano C P Azevedo1, Pedro Caruso2, Ulysses V A Silva3, André P Torelly4, Eliézer Silva5, Ederlon Rezende6, José J Netto7, Claudio Piras8, Suzana M A Lobo9, Marcos F Knibel10, José M Teles11, Ricardo A Lima12, Bruno S Ferreira13, Gilberto Friedman3, Alvaro Rea-Neto14, Felipe Dal-Pizzol15, Fernando A Bozza16, Jorge I F Salluh17, Márcio Soares18. 1. ICU, Hospital Sirio-Libanes, Criciúma, Brazil; Programa de Pós-Graduação em Oncologia, Criciúma, Brazil. 2. ICU, Hospital A. C. Camargo, Criciúma, Brazil. 3. ICU, Universidade Federal do Rio Grande do Sul, Porto Alegre, Criciúma, Brazil. 4. ICU, Santa Casa de Misericórdia de Porto Alegre, Criciúma, Brazil. 5. ICU, Hospital Israelita Albert Einstein, Criciúma, Brazil; ICU, Fundação Pio XII, Hospital do Câncer de Barretos, Barretos, Criciúma, Brazil. 6. ICU, Hospital do Servidor Público Estadual, São Paulo, Criciúma, Brazil. 7. ICU, Instituto Nacional de Câncer, Hospital do Câncer II, Criciúma, Brazil. 8. ICU, Vitória Apart Hospital, Vitória, Criciúma, Brazil. 9. Division of Critical Care Medicine, Department of Internal Medicine, Medical School and Hospital de Base, São José do Rio Preto, Criciúma, Brazil. 10. ICU, Hospital São Lucas, Criciúma, Brazil. Electronic address: marciosoaresms@gmail.com. 11. ICU, Hospital Português, Salvador, Criciúma, Brazil. 12. ICU, Hospital Samaritano, Criciúma, Brazil. 13. Hospital Pasteur, Criciúma, Brazil. 14. ICU, Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, Criciúma, Brazil. 15. Laboratório de Fisiopatologia Experimental, Programa de Pós-Graduação Ciências da Saúde, Unidade Acadêmica de Ciências da Saúde, Universidade do Extremo Sul Catarinense, Criciúma, Brazil. 16. D'Or Institute for Research and Education, Rio de Janeiro, Criciúma, Brazil. 17. Programa de Pós-Graduação em Oncologia, Criciúma, Brazil. 18. Programa de Pós-Graduação em Oncologia, Criciúma, Brazil; D'Or Institute for Research and Education, Rio de Janeiro, Criciúma, Brazil.
Abstract
BACKGROUND: This study was undertaken to evaluate the clinical characteristics and outcomes of patients with cancer requiring nonpalliative ventilatory support. METHODS: This was a secondary analysis of a prospective cohort study conducted in 28 Brazilian ICUs evaluating adult patients with cancer requiring invasive mechanical ventilation (MV) or noninvasive ventilation (NIV) during the first 48 h of their ICU stay. We used logistic regression to identify the variables associated with hospital mortality. RESULTS: Of 717 patients, 263 (37%) (solid tumors = 227; hematologic malignancies = 36) received ventilatory support. NIV was initially used in 85 patients (32%), and 178 (68%) received MV. Additionally, NIV followed by MV occurred in 45 patients (53%). Hospital mortality rates were 67% in all patients, 40% in patients receiving NIV only, 69% when NIV was followed by MV, and 73% in patients receiving MV only (P < .001). Adjusting for the type of admission, newly diagnosed malignancy (OR, 3.59; 95% CI, 1.28-10.10), recurrent or progressive malignancy (OR, 3.67; 95% CI, 1.25-10.81), tumoral airway involvement (OR, 4.04; 95% CI, 1.30-12.56), performance status (PS) 2 to 4 (OR, 2.39; 95% CI, 1.24-4.59), NIV followed by MV (OR, 3.00; 95% CI, 1.09-8.18), MV as initial ventilatory strategy (OR, 3.53; 95% CI, 1.45-8.60), and Sequential Organ Failure Assessment score (each point except the respiratory domain) (OR, 1.15; 95% CI, 1.03-1.29) were associated with hospital mortality. Hospital survival in patients with good PS and nonprogressive malignancy and without tumoral airway involvement was 53%. Conversely, patients with poor functional capacity and cancer progression had unfavorable outcomes. CONCLUSIONS: Patients with cancer with good PS and nonprogressive disease requiring ventilatory support should receive full intensive care, because one-half of these patients survive. On the other hand, provision of palliative care should be considered the main goal for patients with poor PS and progressive underlying malignancy.
BACKGROUND: This study was undertaken to evaluate the clinical characteristics and outcomes of patients with cancer requiring nonpalliative ventilatory support. METHODS: This was a secondary analysis of a prospective cohort study conducted in 28 Brazilian ICUs evaluating adult patients with cancer requiring invasive mechanical ventilation (MV) or noninvasive ventilation (NIV) during the first 48 h of their ICU stay. We used logistic regression to identify the variables associated with hospital mortality. RESULTS: Of 717 patients, 263 (37%) (solid tumors = 227; hematologic malignancies = 36) received ventilatory support. NIV was initially used in 85 patients (32%), and 178 (68%) received MV. Additionally, NIV followed by MV occurred in 45 patients (53%). Hospital mortality rates were 67% in all patients, 40% in patients receiving NIV only, 69% when NIV was followed by MV, and 73% in patients receiving MV only (P < .001). Adjusting for the type of admission, newly diagnosed malignancy (OR, 3.59; 95% CI, 1.28-10.10), recurrent or progressive malignancy (OR, 3.67; 95% CI, 1.25-10.81), tumoral airway involvement (OR, 4.04; 95% CI, 1.30-12.56), performance status (PS) 2 to 4 (OR, 2.39; 95% CI, 1.24-4.59), NIV followed by MV (OR, 3.00; 95% CI, 1.09-8.18), MV as initial ventilatory strategy (OR, 3.53; 95% CI, 1.45-8.60), and Sequential Organ Failure Assessment score (each point except the respiratory domain) (OR, 1.15; 95% CI, 1.03-1.29) were associated with hospital mortality. Hospital survival in patients with good PS and nonprogressive malignancy and without tumoral airway involvement was 53%. Conversely, patients with poor functional capacity and cancer progression had unfavorable outcomes. CONCLUSIONS:Patients with cancer with good PS and nonprogressive disease requiring ventilatory support should receive full intensive care, because one-half of these patients survive. On the other hand, provision of palliative care should be considered the main goal for patients with poor PS and progressive underlying malignancy.
Authors: Frank Daniel Martos-Benítez; Andrés Soto-García; Anarelys Gutiérrez-Noyola Journal: J Cancer Res Clin Oncol Date: 2018-01-23 Impact factor: 4.553
Authors: Neha N Goel; Clark Owyang; Shamsuddoha Ranginwala; George T Loo; Lynne D Richardson; Kusum S Mathews Journal: Respir Care Date: 2019-10-01 Impact factor: 2.258
Authors: Elie Azoulay; Peter Schellongowski; Michael Darmon; Philippe R Bauer; Dominique Benoit; Pieter Depuydt; Jigeeshu V Divatia; Virginie Lemiale; Maarten van Vliet; Anne-Pascale Meert; Djamel Mokart; Stephen M Pastores; Anders Perner; Frédéric Pène; Peter Pickkers; Kathryn A Puxty; Francois Vincent; Jorge Salluh; Ayman O Soubani; Massimo Antonelli; Thomas Staudinger; Michael von Bergwelt-Baildon; Marcio Soares Journal: Intensive Care Med Date: 2017-07-19 Impact factor: 17.440